Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.

After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.

Sanofi has appointed Mike Quigley, a former executive at Gilead and Bristol Myers Squibb, as the French pharma's next chief ...

Amgen's immunology drug results —The Novo Nordisk Senate hearing —Sanofi's soul-searching Read on to learn more.

Ranking Member of the Transportation, Housing and Urban Development Appropriations Subcommittee, joins John Williams to ...

NEW YORK, Sept 23 (Reuters) - Sanofi's (SASY.PA), opens new tab chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new ...

Banks and other lenders are readying over €10B ($11.1B) in funding as New York-based buyout firm Clayton Dubilier & Rice and its French rival PAI Partners compete for Sanofi’s (NASDAQ ...

Sept 24 (Reuters) - Sanofi (SASY.PA), opens new tab has received two separate bids from private equity firms for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion ...

Rep. Mike Quigley (D-Ill.) said Biden “has to be honest with himself” and warned that his decision to run for reelection could hurt Democrats down the ballot. “We have to be honest with ours ...

CHICAGO — Illinois Rep. Mike Quigley on Friday became the first high-profile Democrat in the state and the fourth member of ...

METHODOLOGY: The numbers on this page are calculated from contributions of more than $200 from individuals, as reported to the Federal Election Commission. PAC dollars are not included. NOTE: All the ...